Immunohistochemical Expression and Clinical Significance of Suggested Stem Cell Markers in Hepatocellular Carcinoma
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Increasing evidence has shown that tumor initiation and growth are nourished by a small subpopulation of cancer stem cells (CSCs) within the tumor mass. CSCs are posited to be responsible for tumor maintenance, growth, distant metastasis, and relapse after curative operation. We examined the expression of CSC markers in paraffin-embedded tissue sections of hepatocellular carcinoma (HCC) and correlated the results with clinicopathologic characteristics. Methods: Immunohistochemical staining for the markers believed to be expressed in the CSCs, including epithelial cell adhesion molecule (EpCAM), keratin 19 (K19), CD133, and CD56, was performed in 82 HCC specimens. Results: EpCAM expression was observed in 56% of the HCCs (46/82) and K19 in 6% (5/82). EpCAM expression in HCC significantly correlated with elevated α-fetoprotein level, microvessel invasion of tumor cells, and high histologic grade. In addition, Ep-CAM expression significantly correlated with K19 expression. The overall survival and relapse-free survival rates in patients with EpCAM-expressing HCC were relatively lower than those in patients with EpCAM-negative HCC. All but two of the 82 HCCs were negative for CD133 and CD56, respectively. Conclusions: Our results suggest that HCCs expressing EpCAM are associated with unfavorable prognostic factors and have a more aggressive clinical course than those not expressing EpCAM. Further, the expression of either CD133 or CD56 in paraffin-embedded HCC tissues appears to be rare.
Abstract
Background: Increasing evidence has shown that tumor initiation and growth are nourished by a small subpopulation of cancer stem cells (CSCs) within the tumor mass. CSCs are posited to be responsible for tumor maintenance, growth, distant metastasis, and relapse after curative operation. We examined the expression of CSC markers in paraffin-embedded tissue sections of hepatocellular carcinoma (HCC) and correlated the results with clinicopathologic characteristics. Methods: Immunohistochemical staining for the markers believed to be expressed in the CSCs, including epithelial cell adhesion molecule (EpCAM), keratin 19 (K19), CD133, and CD56, was performed in 82 HCC specimens. Results: EpCAM expression was observed in 56% of the HCCs (46/82) and K19 in 6% (5/82). EpCAM expression in HCC significantly correlated with elevated α-fetoprotein level, microvessel invasion of tumor cells, and high histologic grade. In addition, Ep-CAM expression significantly correlated with K19 expression. The overall survival and relapse-free survival rates in patients with EpCAM-expressing HCC were relatively lower than those in patients with EpCAM-negative HCC. All but two of the 82 HCCs were negative for CD133 and CD56, respectively. Conclusions: Our results suggest that HCCs expressing EpCAM are associated with unfavorable prognostic factors and have a more aggressive clinical course than those not expressing EpCAM. Further, the expression of either CD133 or CD56 in paraffin-embedded HCC tissues appears to be rare.
참고문헌 (28)
- Torre LA, "Global cancer statistics, 2012", CA Cancer J Clin, 65, pp.87~108 (2015)
- El-Serag HB, "Diagnosis and treatment of hepatocellular carcinoma", Gastroenterology, 134, pp.1752~1763 (2008)
- Visvader JE, "Cells of origin in cancer", Nature, 469, pp.314~322 (2011)
- Clarke MF, "Cancer stem cells: perspectives on current status and future directions: AACR Workshop on cancer stem cells", Cancer Res, 66, pp.9339~9344 (2006)
- Bomken S, "Understanding the cancer stem cell", Br J Cancer, 103, pp.439~445 (2010)
- Bjerkvig R, "Opinion:the origin of the cancer stem cell: current controversies and new insights", Nat Rev Cancer, 5, pp.899~904 (2005)
- Marquardt JU, "Epigenetic regulation of cancer stem cells in liver cancer: current concepts and clinical implications", J Hepatol, 53, pp.568~577 (2010)
- Yamashita T, "EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem", progenitor cell features, 2009, pp.136, 1012~1024
- Durnez A, "The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma: a possible progenitor cell origin", Histopathology, 49, pp.138~151 (2006)
- Zhu Z, "Cancer stem", progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma, 2010, pp.126, 2067~2078
- Chan AW, "Expression of stemness markers(CD133 and EpCAM)in prognostication of hepatocellular carcinoma", Histopathology, 64, pp.935~950 (2014)
- Edge SB, "AJCC cancer staging manual" (2010), Springer
- Visvader JE, "Cancer stem cells: current status and evolving complexities", Cell Stem Cell, 10, pp.717~728 (2012)
- Yang XR, "High expression levels of putative hepatic stem", progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma, 2010, pp.59, 953~962
- Kim H, "Human hepatocellular carcinomas with “Stemness”-related marker expression: keratin 19 expressionand a poor prognosis", Hepatology, 54, pp.1707~1717 (2011)
- Guo Z, "Cancer stem cell markers correlate with early recurrence and survival in hepatocellular carcinoma", World J Gastroenterol, 20, pp.2098~2106 (2014)
- Litvinov SV, "Epithelial cell adhesion molecule (Ep-CAM) modulates cell-cell interactions mediated by classic cadherins", J Cell Biol, 139, pp.1337~1348 (1997)
- Went PT, "Frequent EpCAM protein expression in human carcinomas", Hum Pathol, 35, pp.122~128 (2004)
- Breuhahn K, "Expression of epithelial cellular adhesion molecule (Ep-CAM) in chronic (necro-)inflammatory liver diseases and hepatocellular carcinoma", Hepatol Res, 34, pp.50~56 (2006)
- Yamashita T, "EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma", Cancer Res, 68, pp.1451~1461 (2008)
- Govaere O, "Keratin 19: a key role player in the invasion of human hepatocellular carcinomas", Gut, 63, pp.674~685 (2014)
- Shan YF, "Angiogenesis and clinicopathologic characteristics in different hepatocellular carcinoma subtypes defined by EpCAM and alpha-fetoprotein expression status", Med Oncol, 28, pp.1012~1016 (2011)
- Kimura O, "Expression of EpCAM increases in the hepatitis B related and the treatment-resistant hepatocellular carcinoma", Biomed Res Int, 2014, pp.172913~ (2014)
- Kim H, "Hepatocellular carcinomas expressing ‘stemness’-related markers: clinicopathological characteristics", Dig Dis, 32, pp.778~785 (2014)
- Zen C, "Mixed phenotype hepatocellular carcinoma after transarterial chemoembolization and liver transplantation", Liver Transpl, 17, pp.943~954 (2011)
- Yeh CT, "CD133-positive hepatocellular carcinoma in an area endemic for hepatitis B virus infection", BMC Cancer, 9, pp.324~ (2009)
- Tsuchiya A, "Clinicopathological analysis of CD133 and NCAM human hepatic stem", progenitor cells in damaged livers and hepatocellular carcinomas, 2009, pp.39, 1080~1090
- Tsuchiya A, "Hepatocellular carcinoma with progenitor cell features distinguishable by the hepatic stem", progenitor cell marker NCAM, 2011, pp.309, 95~103